Incyte Corp. (INCY)
115.30
-1.84
(-1.57%)
USD |
NASDAQ |
Oct 02, 16:00
115.30
0.00 (0.00%)
After-Hours: 20:00
Incyte Gross Profit Margin (Quarterly) : 92.57% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 92.57% |
| March 31, 2026 | 90.46% |
| December 31, 2025 | 90.88% |
| September 30, 2025 | 91.50% |
| June 30, 2025 | 92.13% |
| March 31, 2025 | 91.49% |
| December 31, 2024 | 91.08% |
| September 30, 2024 | 91.00% |
| June 30, 2024 | 91.09% |
| March 31, 2024 | 91.24% |
| December 31, 2023 | 91.53% |
| September 30, 2023 | 91.75% |
| June 30, 2023 | 91.31% |
| March 31, 2023 | 91.27% |
| December 31, 2022 | 92.23% |
| September 30, 2022 | 91.99% |
| June 30, 2022 | 93.23% |
| March 31, 2022 | 92.68% |
| December 31, 2021 | 93.82% |
| September 30, 2021 | 93.95% |
| June 30, 2021 | 93.33% |
| March 31, 2021 | 93.77% |
| December 31, 2020 | 94.41% |
| September 30, 2020 | 93.25% |
| June 30, 2020 | 94.11% |
| Date | Value |
|---|---|
| March 31, 2020 | 93.84% |
| December 31, 2019 | 93.05% |
| September 30, 2019 | 93.02% |
| June 30, 2019 | 92.93% |
| March 31, 2019 | 93.76% |
| December 31, 2018 | 93.32% |
| September 30, 2018 | 92.61% |
| June 30, 2018 | 93.68% |
| March 31, 2018 | 93.16% |
| December 31, 2017 | 93.26% |
| September 30, 2017 | 92.51% |
| June 30, 2017 | 91.66% |
| March 31, 2017 | 93.63% |
| December 31, 2016 | 91.30% |
| September 30, 2016 | 92.50% |
| June 30, 2016 | 92.37% |
| March 31, 2016 | 95.62% |
| December 31, 2015 | 93.85% |
| September 30, 2015 | 92.74% |
| June 30, 2015 | 92.71% |
| March 31, 2015 | 90.70% |
| December 31, 2014 | 88.18% |
| September 30, 2014 | 94.91% |
| June 30, 2014 | 90.07% |
| March 31, 2014 | 89.10% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 83.68% |
| Mirum Pharmaceuticals, Inc. | 82.65% |
| Vertex Pharmaceuticals, Inc. | 85.37% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| AbbVie, Inc. | 74.71% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 31.06% |
| Return on Assets | 23.48% |
| Return on Invested Capital | 30.80% |
| Profit Margin (Quarterly) | 34.98% |
| Operating Margin (Quarterly) | 41.84% |
| Return on Net Operating Assets | 75.93% |